A Canadian Study of Cisplatin Metabolomics and Nephrotoxicity (ACCENT): A Clinical Research Protocol

Background: Cisplatin, a chemotherapy used to treat solid tumors, causes acute kidney injury (AKI), a known risk factor for chronic kidney disease and mortality. AKI diagnosis relies on biomarkers which are only measurable after kidney damage has occurred and functional impairment is apparent; this...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anshika Jain, Ryan Huang, Jasmine Lee, Natasha Jawa, Yong Jin Lim, Mike Guron, Sharon Abish, Paul C. Boutros, Michael Brudno, Bruce Carleton, Geoffrey D. E. Cuvelier, Lakshman Gunaratnam, Cheryl Ho, Khosrow Adeli, Sara Kuruvilla, Giles Lajoie, Geoffrey Liu, Paul C. Nathan, Shahrad Rod Rassekh, Michael Rieder, Sushrut S. Waikar, Stephen A. Welch, Matthew A. Weir, Eric Winquist, David S. Wishart, Alexandra P. Zorzi, Tom Blydt-Hansen, Michael Zappitelli, Bradley Urquhart
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Diseases of the genitourinary system. Urology RC870-923
Acceso en línea:	https://doaj.org/article/15b7986c609a42cb8982f5a706c42a37
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

A Canadian Study of Cisplatin Metabolomics and Nephrotoxicity (ACCENT): A Clinical Research Protocol

Ejemplares similares